In summary, to alleviate the disadvantages of STING agonists (poor stability, low delivery efficiency, and potential toxicity) and reduce the potential renal fibrosis and brain deposition caused by GBCAs, a Turbo‐charging system‐like GBCA, termed as Turbo S, was designed and constructed for MRI‐guided STING pathway‐activated cancer immunotherapy. The gene discussed is STING1; the disease is renal fibrosis.